ROS-augmented and tumor-microenvironment responsive biodegradable nanoplatform for enhancing chemo-sonodynamic...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Reactive oxygen species (ROS) generation within the tumor microenvironment (TME) is a key strategy for cancer treatment.
• Developing effective nanocarriers that can augment ROS efficacy is crucial for advancing cancer therapy.

Purpose of the Study:

• To design a smart, biodegradable nanoplatform for targeted cancer therapy.
• To combine chemotherapy and sonodynamic therapy (SDT) using ultrasound for enhanced tumor treatment.

Main Methods:

• A novel nanoplatform was engineered with mitochondrial targeting, pH-responsive drug release, and enzyme-like catalytic functions.
• The nanoplatform co-loaded Ce6 and DOX, utilizing ultrasound as an excitation source for ROS generation.
• In vitro and in vivo experiments were conducted to evaluate drug release, biosafety, tumor targeting, and therapeutic efficacy.

Main Results:

• The nanoplatform demonstrated pH-responsive degradation and controlled release of DOX (63.91 ± 1.67%) in vitro.
• In vivo studies confirmed excellent biosafety, tumor site accumulation, and rapid clearance from the body within 24 hours.
• Complete tumor elimination and long-term survival without recurrence were observed in mice after 60 days post-treatment.

Conclusions:

• The developed nanoplatform effectively integrates chemotherapy and SDT through mitochondrial targeting and enhanced ROS generation.
• The platform leverages the TME's acidic nature for accelerated drug release and platinum nanoparticles for increased oxygen content, boosting SDT efficacy.
• This research offers a promising new strategy for developing ROS-based nanocarriers for malignant tumor treatment.